HCPLive

New Meningitis B Vaccine Strongly Immunogenic

Tuesday, May 8 (HealthDay News) -- Peter C. Richmond, M.B.B.S., from the Princess Margaret Hospital for Children in Subiaco, Australia, and colleagues randomly assigned 511 healthy adolescents to placebo or one of three doses of a vaccine against Neisseria meningitidis serogroup B (recombinant lipoprotein 2086) at zero, two, and six months.

As determined by serum bactericidal assays using human complement (hSBA) against eight strains, the researchers found that seroconversion occurred in 67.9 to 100 percent of subjects at the two highest doses. The immune response was strong, with many having titers up to 16. The vaccine was generally well tolerated, with mild-to-moderate pain at the injection site being the most common local reaction. Systemic events were generally mild to moderate and included fatigue and headache. There was one serious vaccine-related adverse event, which resolved without sequelae, after the third dose of the highest dose.

"The bivalent recombinant lipoprotein 2086 vaccine is immunogenic and induces robust hSBA activity against diverse invasive meningococcus serogroup B disease strains, and the vaccine is well tolerated," Richmond and colleagues conclude. "Recombinant lipoprotein 2086 vaccine is a promising candidate for broad protection against invasive meningococcus serogroup B disease."

Several authors disclosed financial ties to pharmaceutical companies, including Wyeth and Pfizer, both of which funded the study.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

A new meningococcus serogroup B vaccine is strongly immunogenic against multiple strains and well tolerated in healthy adolescents, according to a study published online May 7 in The Lancet Infectious Diseases.

Copyright © 2012 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Medications in general can take a long time to develop. Depending on the condition they treat that process can be even longer as more questions have to be answered before they can be introduced to the field. This is particularly true of multiple sclerosis treatments.
As a treatment for multiple sclerosis teriflunomide has shown benefits over a long development period and has proven effective in the treatment of patients with the relapsing-remitting form of the condition.
For as many drugs and therapies as there are for multiple sclerosis some are more aggressive than others. Alemtuzumab's approach is more on the aggressive end of the spectrum.
During a time when antibiotic resistance concerns are at an all-time high, a Texas-based team called for backup in the fight against pneumonia.
$vAR$